

---

# 3<sup>rd</sup> Systemic Sclerosis World Congress

6-8 February 2014 – Rome, Italy

---

## Abstracts

---

### Honorary Presidents

C. Black, S. Jablonska  
F. Wollheim, T. Medsger

### Steering Committee

D.E. Furst, M. Matucci-Cerinic, A. Tyndall  
U. Müller-Ladner, L. Guillemin, K. Takehara  
J. Seibold, and the following Chairpersons:

Chairpersons of the Abstract Committee

**O. Distler, P. Sampaio Barros**

Chairpersons of the Clinical Committee

**Y. Allanore, D. Khanna**

Chairpersons of the Basic Committee

**J. Varga, J. Distler**

Chairperson of the Workshops

**P. Clements**

Liaison officers with the Scleroderma Workshop

**C. Denton, R. Lafyatis**

Chairpersons of the Mentoring Programme

**L. Czirjak, M. Mayes**

### Scientific Committee

D. Abraham, M. Baron, P. Carreira, M. Cutolo,  
N. Damjanov, F. Del Galdo, J. Distler, A. Gabrielli, S. Gay,  
R. Giacomelli, E. Hachulla, A. Herrick, M. Inanc,  
B. Kahaleh, R. Knobler, O. Kowal-Bielecka, T. Krieg,  
M. Kuwana, M.T. Li, P. Merkel, J. Pope, S. Rednic,  
G. Riemekasten, S. Sato, J. Scali, Y. Shoenfeld, R. Silver,  
V. Steen, R. Simms, M. Trojanowska, G. Valentini,  
F. van den Hoogen, J. van Laar, U. Walker, A. Wells, F. Wigley

### FESCA Board

A. Tyrrell Kennedy, *President*  
B. Garay-Toh, *Vice-President*  
D. Demetriou-Charalambous, *Treasurer*  
Alexandra Portales, *Secretary*  
C. van den Bosch, *Legal Advisor*

---

## CONTENTS

### SESSION 1 - MANAGEMENT AND ASSESSMENT OF NEWLY DIAGNOSED SSC

<b>S1.2</b>	NEW EULAR/ACR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN CLINICAL PRACTICE	S-5
<b>S1.3</b>	2013 CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS AN AMERICAN COLLEGE OF RHEUMATOLOGY/EUROPEAN LEAGUE AGAINST RHEUMATISM COLLABORATIVE INITIATIVE	S-5
<b>S1.4</b>	PERFORMANCE OF THE OLD 1980 ACR AND THE NEW ACR-EULAR SYSTEMIC SCLEROSIS (SSC) CLASSIFICATION CRITERIA IN PATIENTS WITH LIMITED CUTANEOUS SSC	S-6
<b>S1.5</b>	EARLY ACCRUAL OF ORGAN DAMAGE IN SCLERODERMA: RATIONALE FOR DERIVATION AND VALIDATION OF A DISEASE DAMAGE INDEX IN SYSTEMIC SCLEROSIS	S-6
<b>S1.6</b>	PERFORMANCE OF THE 2013 ACR/EULAR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN A SINGLE CENTER SETTING	S-7
<b>S1.7</b>	SSC INTRINSIC SUBSET CLASSIFICATION IN PATIENTS THAT DEMONSTRATE CLINICAL IMPROVEMENT DURING TREATMENT	S-7

### SESSION 2 - MISCELLANEOUS AND DIFFERENTIAL DIAGNOSIS OF SSC

<b>S2.1</b>	HOW TO DIFFERENTIATE SSC FROM SCLERODERMA- LIKE DISORDER?	S-8
<b>S2.2</b>	GENDER EFFECTS ON SYSTEMIC SCLEROSIS PHENOTYPE: A LONGITUDINAL EUSTAR STUDY BASED ON MORE THAN 10 000 PATIENTS	S-8
<b>S2.3</b>	EPIDEMIOLOGY OF CANCER IN SYSTEMIC SCLEROSIS. SYSTEMATIC REVIEW AND META-ANALYSIS OF CANCER INCIDENCE, PREDICTORS AND MORTALITY	S-8
<b>S2.4</b>	JOINT AND TENDON INVOLVEMENT PREDICT SEVERE DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS: A EUSTAR PROSPECTIVE STUDY	S-9

### SESSION 3 - THE GREAT DEBATE

<b>S3.1</b>	THE PLACE OF CORTICOSTEROIDS IN SSC	S-9
-------------	-------------------------------------	-----

### SESSION 4 - AN INTEGRATED APPROACH TO GASTRO-INTESTINAL INVOLVEMENT

<b>S4.1</b>	GI: HOW TO EVALUATE, DIAGNOSE AND TREAT UPPER AND LOWER GI INVOLVEMENT	S-10
<b>S4.2</b>	NEW THERAPEUTIC APPROACHES	S-10
<b>S4.3</b>	MORTALITY, RECURRENCE, AND HOSPITAL COURSE OF PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) RELATED ACUTE INTESTINAL PSEUDO-OBSTRUCTION	S-10
<b>S4.4</b>	PREVALENCE, CORRELATES AND OUTCOMES OF GASTRIC ANTRAL VASCULAR ECTASIA IN SYSTEMIC SCLEROSIS : A EUSTAR CASE-CONTROL STUDY	S-10

### SESSION 5 - LINKS TO INFLAMMATION, IMMUNITY AND VASCULAR DISEASE

<b>S5.1</b>	IMMUNOLOGICAL MECHANISMS OF FIBROSIS	S-11
<b>S5.2</b>	PIGMENT EPITHELIUM DERIVED FACTOR SECRETED BY SSC FIBROBLASTS INHIBITS ANGIO AND VASCULOGENESIS <i>IN VITRO</i>	S-11
<b>S5.3</b>	SCLERODERMA DERMAL FIBROBLASTS OVEREXPRESS VASCULAR ENDOTHELIAL GROWTH FACTOR DUE TO AUTOCRINE TRANSFORMING GROWTH FACTOR BETA SIGNALING	S-12
<b>S5.4</b>	IL6 TRANS-SIGNALING AND CCL2 CO-REGULATE FIBROBLAST DEPENDENT TRANS-ENDOTHELIAL MIGRATION OF MONONUCLEAR CELLS AND FIBROTIC RESPONSE IN SCLERODERMA	S-12
<b>S5.5</b>	THE GLOBAL MICRORNA PROFILE OF SKIN IN SYSTEMIC SCLEROSIS	S-12
<b>S5.6</b>	THE PRESENCE OF A COLD TEMPERATURE SENSOR IN THE VASCULAR ENDOTHELIUM: ENHANCED EXPRESSION IN SSC SKIN AND ENDOTHELIAL CELLS DYSFUNCTION AFTER ACTIVATION	S-13

**SESSION 7 - TREATMENT AND DMARDS IN SSC**

<b>S7.1</b>	HOW TO TREAT RAPIDLY PROGRESSIVE SSC	S-13
-------------	--------------------------------------	------

**SESSION 8 - MECHANISM OF FIBROSIS**

<b>S8.2</b>	SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) REGULATES TRANSFORMING GROWTH FACTOR-BETA INDUCED FIBROSIS IN SYSTEMIC SCLEROSIS	S-14
<b>S8.3</b>	INVESTIGATING THE ROLE OF MYOCARDIN RELATED TRANSCRIPTION FACTOR (MRTF) IN SYSTEMIC SCLEROSIS (SSC)	S-14
<b>S8.4</b>	EPHRIN B2 IS OVEREXPRESSED IN HUMAN SCLERODERMA SKIN AND MEDIATES FIBROBLAST TO MYOFIBROBLAST DIFFERENTIATION, AND INDUCES FIBROSIS IN MICE	S-14
<b>S8.5</b>	EXPERIMENTAL RENAL INJURY IN A TGFBETA DEPENDENT MOUSE MODEL OF SCLERODERMA	S-15
<b>S8.6</b>	DIRECT THROMBIN INHIBITOR DABIGATRAN ETEXILATE PROTECTS ALVEOLAR EPITHELIAL CELLS FROM APOPTOSIS IN A BLEOMYCIN MODEL OF SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE	S-15
<b>S8.7</b>	STIMULATION OF THE SOLUBLE GUANYLATE CYCLASE (SGC) INHIBITS DERMAL FIBROSIS BY BLOCKING NON-CANONICAL TGF-BETA-SIGNALING	S-15

**SESSION 10 - CARDIOVASCULAR INVOLVEMENT**

<b>S10.1</b>	CONDUCTION AND RHYTHM DEFECTS IN SCLERODERMA	S-16
<b>S10.2</b>	IMPROVEMENT OF DIGITAL ULCERATIVE DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS IS ASSOCIATED WITH BETTER FUNCTIONAL PROGNOSIS	S-16
<b>S10.3</b>	PREDICTION OF CARDIAC AND VASCULAR EVENTS IN SYSTEMIC SCLEROSIS: INPUT FROM ENDOTHELIN-1 TYPE A RECEPTOR ANTIBODIES	S-17

**SESSION 11 - INTERSTITIAL LUNG DISEASE**

<b>S11.1</b>	SSC-ILD: WHO TO TREAT AND HOW TO TREAT?	S-17
<b>S11.2</b>	PROGRESSIVE DETERIORATION OF PATIENTS WITH SCLERODERMA WITH PULMONARY INVOLVEMENT: 11-YEAR OUTCOMES FROM THE SCLERODERMA LUNG STUDY (SLS1)	S-17
<b>S11.3</b>	SURVIVAL AFTER LUNG TRANSPLANTATION IN SYSTEMIC SCLEROSIS. A SYSTEMATIC REVIEW	S-18
<b>S11.4</b>	GENETIC MARKERS OF SUSCEPTIBILITY AND INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS PATIENTS: AN IMMUNOCHIP STUDY	S-18

**SESSION 12 - PULMONARY ARTERIAL HYPERTENSION**

<b>S12.1</b>	PAH: HOW TO MAKE THE RIGHT DIAGNOSIS AT THE RIGHT TIME	S-19
<b>S12.2</b>	CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY HYPERTENSION AND A PULMONARY CAPILLARY WEDGE PRESSURE >15 IN THE PHAROS REGISTRY	S-19
<b>S12.3</b>	RECOMMENDATIONS FOR SCREENING AND DETECTION OF CONNECTIVE-TISSUE DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION	S-20
<b>S12.4</b>	A COMPARISON OF THE PREDICTIVE ACCURACY OF THREE SCREENING MODELS (DETECT V. ESC/ERS V. ASIG) FOR PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS	S-20
<b>S12.5</b>	CLINICAL SUBTYPE AND AUTOANTIBODIES BOTH HELP PREDICT PULMONARY ARTERIAL HYPERTENSION, BUT AUTOANTIBODIES ARE STRONGER PREDICTORS OF DEVELOPING SECONDARY PULMONARY HYPERTENSION	S-21
<b>S12.6</b>	PROGNOSTIC VALUE OF NT-PROBNP IN SYSTEMIC SCLEROSIS PATIENTS WITHOUT PULMONARY HYPERTENSION	S-21

**SPECIAL LECTURE**

<b>SL1.1</b>	DESSCIPHER, A JUMP IN THE FUTURE	S-22
--------------	----------------------------------	------

**POSTER TOUR - CLINICAL**

Poster Tour 1 – RAYNAUD & ULCERS	S-23-25
PS01 to PS06	
Poster Tour 2 – RAYNAUD & ULCERS	S-25-27
PS07 to PS12	
Poster Tour 3 – PULMONARY / INTERSTITIAL LUNG DISEASE	S-27-29
PS13 to PS19	
Poster Tour 4 – PULMONARY ARTERIAL HYPERTENSION	S-30-33
PS20 to PS27	
Poster Tour 5 – CARDIAC	S-33-35
PS28 to PS34	
Poster Tour 6 – OUTCOMES QUALITY OF LIFE PSYCHOLOGICAL & SOCIAL	S-36-38
PS35 to PS41	
Poster Tour 7 – IMAGING	S-38-41
PS42 to PS48	
Poster Tour 8 – THERAPY / MISCELLANEOUS	S-42-44
PS49 to PS55	
Poster Tour 9 – MUSCULOSKELETAL SYSTEM & REHABILITATION	S-44-46
PS56 to PS 61	
Poster Tour 10 – UPPER AND LOWER GASTROINTESTINAL/NUTRITION	S-47-49
PS62 to PS68	
Poster Tour 11 – PREGNANCY & SEXUAL PROBLEMS	S-49-51
PS69 to PS73	
Poster Tour 12 – THERAPY	S-51-54
PS74 to PS82	

**POSTER TOUR – BASIC**

Poster Tour 13 – PATHOGENESIS	PS83 TO PS94	S-54-58
Poster Tour 14 – PATHOGENESIS	PS95 TO PS102	S-58-61
Poster Tour 15 – PATHOGENESIS	PS103 TO PS111	S-61-64

**POSTER SESSION**

PS112 TO PS356	S-65-146
----------------	----------

**INDEX**

S-147
-------